Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a “springboard year,” driven in part by what he described as a significant amount of ...

Wegovy is now available as a daily pill, but experts say strict dosing schedules and more intense side effects may not make it a better option than the injection.

Your body needs vitamin A each day for healthy vision. Consume vitamin A-rich foods or dietary supplements consistently along ...

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Apply to become a Senior Planet sponsored athlete to motivate ...

SaveHealth reports on cholesterol medications, detailing common types like statins, their effects, and safety considerations ...

The drug manufacturing giant is expected to announce its fiscal fourth-quarter earnings for 2025 in the near term. Ahead of ...

Check out some of the medications affected by drugmakers raising prices on life-saving medications this year, as well as some ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a ...

Patients receiving Repatha achieved a median LDL cholesterol level of 45 mg/dL compared to 109 mg/dL in the placebo group. "Repatha has once again demonstrated its ability to protect patients from the ...

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...